Tsinghua University developed detection kit: a blood test for lung cancer | | | tumor markers _ Tsinghua news

Legal evening news (reporters Wang Hejian) Tsinghua University research group at the international level for the first time proved that human heat shock protein Hsp90 alpha (hereinafter referred to as persons 90-α) as a new tumor marker, and developed a quantitative assay Kit. Just a drop of blood of lung cancer patients, it can be used for monitoring and evaluation of treatment effect. Next, the research results may also be applied to the detection of a variety of cancers, such as liver cancer, stomach cancer.

At this morning's press conference, Tsinghua University professor Luo Yongzhang, Director of national engineering laboratories, anti-tumor protein drugs, presented his findings: men 90-α was found over the years, Tsinghua University team prove to be an entirely new tumor marker for the first time.

It is understood that the tumor markers are a class of substances reflect the existence of tumor, tumor patient levels, far more than in healthy people. Markers, or variable, you can prompt the tumor is. Have now become important adjunct in cancer diagnosis and treatment guidelines. Research Group of Luo Yongzhang proves that people 90 Alpha is a new tumor markers.

Recognizing that with that in mind, Luo Yongzhang group collaboration with biotech companies soon, developed a stable performance 90 Alpha kits for quantitative detection of persons, and in 2010 the medical device manufacturing license.

Compared with other cancer detection means, using tumor marker detection easier and faster, the cost is significantly reduced. For example, just take a drop of blood of lung cancer patients, through their research and development of test kits, plasma 90 Alpha content, can be used for monitoring and evaluation of the treatment effect.

"People 90 Alpha tumor markers with a wide spectrum of features. "Luo Yongzhang said people 90 alpha used for liver cancer, stomach cancer, breast cancer, pancreatic cancer, more than other types of cancer clinical trials, will be completed in the near future.

(Original title: a blood test for lung cancer tumor marker argument can detect a wide range of cancers in the future for the first time, Tsinghua University)

(Edit: SN082)
November 17, 2013 Legal evening news
(
清华研发检测试剂盒：一滴血可验肺癌|清华|肿瘤|标志物_新闻资讯

　　法制晚报讯(记者 王贺健)清华课题组首次在国际上证明，人热休克蛋白Hsp90α(以下简称人90α)为一个全新的肿瘤标志物，并研发出定量检测试剂盒。只需肺癌患者的一滴血，就可用于病情监测和治疗效果评价。未来，这个研究成果还可能应用于肝癌、胃癌等多种癌症的检测。

　　在今天上午的发布会上，清华大学教授、抗肿瘤蛋白质药物国家工程实验室主任罗永章，介绍了他的研究成果：人90α被发现多年以来，清华大学课题组首次证明其是一个全新的肿瘤标志物。

　　据了解，肿瘤标志物是一类反映肿瘤存在的物质，在肿瘤患者体内的含量，远远超过健康人群。标志物的存在或变量，可以提示肿瘤的性质。现已成为肿瘤诊断、治疗指导中的重要辅助手段。罗永章的课题组证明，人90α是一个全新的肿瘤标志物。

　　认识到这一点后，罗永章课题组很快与生物科技公司合作，研发出性能稳定的人90α定量检测试剂盒，并于2010年获得医疗器械生产许可证。

　　与其他肿瘤检测手段相比，利用肿瘤标志物检测更加方便快捷，成本也大大降低。例如，只需取肺癌患者的一滴血，通过他们研发的检测盒，检测血浆中人90α的含量，即可用于病情监测和治疗效果的评价。

　　“人90α肿瘤标志物具有广谱的特性。”罗永章说，人90α用于肝癌、胃癌、乳腺癌、胰腺癌等其他多个癌症种类的临床试验，也将在近期完成。

(原标题：肿瘤标志物 一滴血测肺癌 清华大学首次论证 未来能检测多种癌症)

（编辑：SN082）
2013年11月17日13:30
法制晚报
)